Cairo – Mubasher: The board members of Macro Group Pharmaceuticals - Macro Capital agreed to renew short-term financing from First Abu Dhabi Bank Misr (FABMISR), an Egypt-based unit of the ADX-listed FAB.
The board greenlighted the EGP 65 million facility during its meeting on 21 March 2024, according to a bourse disclosure.
In the first nine months (9M) of 2023, the EGX-listed firm logged consolidated net profits after tax amounting to EGP 98.10 million, an annual drop from EGP 129.49 million.
Sales increased to EGP 589.53 million in 9M-23 from EGP 520.30 million in 9M-22, while the basic and diluted earnings per share (EPS) declined to EGP 0.17 from EGP 0.23.
